Affiliation:
1. Peoples’ Friendship University of Russia
2. Inozemtsev City Clinical Hospital
3. Pirogov Russian National Research Medical University
4. Inozemtsev City Clinical Hospital; Pirogov Russian National Research Medical University
Abstract
Introduction. The relevance of studying the mechanisms underlying the development of adenomyosis is determined not only by its high prevalence reaching 40% among reproductive aged women, but also by its association with unexplained infertility (60%), as well as woman’s quality of life impairment.Aim. To enhance efficiency of therapy after surgical treatment of endometriosis and minimize the risk of disease recurrence.Materials and methods. In a cohort prospective comparative study conducted on the basis of the gynecological department of the Inozemtsev City Clinical Hospital, 80 patients of reproductive age who underwent organ-preserving treatment for external genital endometriosis and nodular adenomyosis were included. Dienogest (Zafrilla) was prescribed to 65 patients at a dose of 2 mg/day (1 tablet) from day 2 after surgical treatment continuously for 6 months, taking into account contraindications to its use, 15 patients refused to take the drug in the postoperative period, and made up the control group.Results. The results of the study showed that after surgical treatment of external genital endometriosis and the nodular form of adenomyosis and the appointment of suppressive therapy with Zafrilla, after 3 months, the intensity of the pain syndrome was transformed according to the VAS, NRS, B&B scales by one step, and after 6 months it decreased to a slight (p < 0.05), which contributed to the improvement of the quality of life of patients based on the EHP-30 questionnaire. The long-term results of the study allow us to recommend the drug Zafrilla, with high compliance, good tolerance, a favorable safety profile, in order to reduce pain, the intensity of menstrual flow, and prevent recurrence of the disease based on 24 months of observation.Conclusion. An integrated approach to the treatment of external genital endometriosis and nodular adenomyosis, including surgical treatment and suppressive therapy with Zafrilla, made it possible to realize reproductive function in 48% of patients. Taking dienogest for 24 weeks provided effective relief of pain, alleviated the symptoms of the disease, as well as improved the quality of life and realized reproductive plans.
Reference63 articles.
1. Medzhidova AM, Esedova AE. Topical issues of diagnosis and treatment of infertility in women with internal genital endometriosis. Research and Practical Medicine Journal. 2017;4(4):89–98. (In Russ.) https://doi.org/10.17709/2409-2231-2017-4-4-10.
2. Adamyan LV, Andreeva EN. The role of modern hormone modulating therapy in the complex treatment of genital endometriosis. Russian Journal of Human Reproduction. 2011;17(6):66–77. (In Russ.) Available at: https://elibrary.ru/pyrbcf.
3. Orazov MR, Radzinsky VE, Khamoshina MB, Kavteladze EV, Shustova VB, Tsoraeva YuR, Novginov DS. Endometriosis-associated infertility: from myths to harsh reality. Trudnyj Pacient. 2019;17(1-2):6–12. (In Russ.) https://doi.org/10.24411/2074-1995-2019-10001.
4. Yarmolinskaya MI, Rusina EI, Khachaturyan AR, Florova MS. Clinical picture and diagnosis of genital endometriosis. Journal of Obstetrics and Women’s Diseases. 2016;65(5):4–21. (In Russ.) https://doi.org/10.17816/JOWD6554-21.
5. Dzhamalutdinova KM, Kozachenko IF, Gus AI, Adamyan LV. The pathogenesis and diagnosis of adenomyosis: current aspects. Akusherstvo i Ginekologiya (Russian Federation). 2018;(1):29–34. (In Russ.) https://doi.org/10.18565/aig.2018.1.29-34.